Pfizer (NYSE: PFE) says that positive findings from two pivotal Phase III studies of investigational crisaborole topical ointment 2% (formerly AN2728) have been published in the online issue of the Journal of the American Academy of Dermatology.
The detailed results from the Pivotal Phase III studies (AD-301 and AD-302) showed that crisaborole achieved statistically-significant results on primary and secondary endpoints for the treatment of atopic dermatitis (AD) in children two years of age and up and adults versus vehicle ointment alone. Crisaborole treatment-related adverse events were infrequent, mild to moderate in severity, and similar to vehicle ointment.
Crisaborole comes with Anacor acquisition
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze